Vaccine Immunotherapy for Prostate Cancer Without Significant Side Effects

Ohana Vaccines uses a proprietary prime-boost strategy to cause the destruction of established prostate cancer

IMMUNOTHERAPY

IS THE NEW SOLUTION

OPPORTUNITY

With an estimated $19B total prostate cancer treatment cost by 2020, Ohana Vaccine targets the 20-30% of recurrent prostate cancer.

RAPID GROWTH

Ohana Vaccines is on track to complete clinical trials by the end of 2018 and is ready to scale rapidly to production.

QUICK RETURN

A patent is already filed and there are no comparable competitive Immunotherapy treatments.

Prostate Cancer Treatment Opportunities

1,100,000

161,360

~ 30 %

Globally there are 1.11 M new cases and 307,000 deaths.

In 2018, 164,650 men in the US will be diagnosed with prostate cancer and greater than 26,000 will die.

After initial treatment, about

20-30% of men will show signs of cancer recurrence.

 

THE PROBLEM

PROSTATE
CANCER RECURRENCE

Following initial treatments for prostate cancer, 20% to 30% of patients will have a recurrence of the disease.

DEATH FROM CANCER IS INEVITABLE

Additional treatments can extend survival but there is no cure for recurrent prostate cancer.  Metastatic spread of the cancer is inevitable.

STRONG
SIDE
EFFECTS

All current treatments are accompanied by significant side effects reducing the patient’s quality of life.

 

THE SOLUTION

Immunotherapy is the new solution – they only destroy antigen-expressing tumor cells and have no effect on normal cells

Kite Pharma Submits IND for BCMA-Targeting CAR-T Cancer Immunotherapy

Genetic Engineering & Biotechnology News

Aug 8, 2017

Please reload

 
LINKS
ABOUT

davidlubaroff@ohanavaccines.com

Tel: 319-621-7206

David M. Lubaroff, PhD; Founder & Chief Scientific Officer

© 2023 by Ohana Vaccines

Ohana Vaccines, LLC